Literature Reviews
doi: 10.25005/2074-0581-2019-21-3-502-512
DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 1)

M.U. Sharofova1,2, Sh.S. Sagdieva1,2, S.D. Yusufi3

1Center for Research on Innovative Technologies under the Academy of Sciences of the Republic of Tajikistan, Dushanbe, Republic of Tajikistan
2Institute of Avicenna’s Medicine and Pharmacology, Dushanbe, Republic of Tajikistan
3Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

The authors analyzed numerous scientific studies on the problem of type 2 diabetes mellitus (T2DM), the extent of the spread is causing concern among experts around the world. The review examines and analyses the causes of the unrelated increase in the incidence of this pathology, the high risk of severe complications, comorbidities and deaths, reasons for the increase in the prevalence of the disease among children. Taking into account insufficient effectiveness of medical treatment of T2DM using synthetic drugs, the authors cites information on herbal medicine diabetes. The first part of this review examines to epidemiology, modern theories of the development of the disease, the role of endothelium and the importance of its function and dysfunction of T2DM development, analyzing the main cause of death in this pathology. The review also focuses on the issue of the costs of health systems in different countries due to the incidence of T2DM and its complications.

Keywords: type 2 diabetes, T2DM, diabetogenesis, pharmacotherapy, herbal medicine.

Download file:

References
  1. Asfandiyarova NS. Smertnost’ pri sakharnom diabete 2 tipa [Type 2 diabetes mortality]. Sakharniy diabet. 2015;18(4):12-21.
  2. Balabolkin MI. Diabetologiya [Diabetology]. Moscow, RF: Meditsina; 2002. 672 p.
  3. Best Ch. Osnovnye periody v istorii izuchenia diabeta. V: Williamson R. (red.) Diabet [The main periods in the history of the study of diabetes. In: Williamson R. (ed.) Diabetes]. Moscow, RF: Meditsina; 1964. p. 64-193.
  4. Best Ch. Sakharniy diabet [Diabetes mellitus]. Riga, Latvia: Znanie; 1989. 10 p.
  5. Kostikov SE, Demyanenko АN. Istoricheskie predposylki otkrytiya insulina [Historical background to the discovery of insulin]. Vestnik Smolenskoy gosudarstvennoy meditsinsloy akademii. 2013;3:90-7.
  6. Miraj S, Alesaeidi S, Kiani S. A systematic review of the relationship between dystemprament (sue Mizaj) and treatments and management of diseases (Ilaj and Eslah-e-Mizaj). Electronic Physician. 2016;8(12):3378.
  7. Haji AA, Nuraliev Yu, Habbasi M, Sharofova M, Bahromova Z. Contribution of Ibn Sina (Avicenna) to the therapy of vitiligo (from the perspective of the medical system of Avicenna and Evidence-Based Medicine). Dushanbe, RT: Contrast; 2015. 344 p.
  8. Abu Ali ibn Sina (Аvitsennа). Sochineniya. Kanon vrachebnoy nauki. Kniga pervaya. T. 12 [Writings. Canon of Medicine. Book one. Vol. 12]. Dushanbе, RT: Donish; 2010. 735 p.
  9. Abu-Asab M, Amri H, Micozzi M. Avicenna’s medicine: a new translation of the 11th-century canon with practical applications for integrative health care. Rochester, Vermont: Healing Art Press; 2013. 462 р.
  10. Nuraliev YuN. Meditsinckaya sistema Ibn Siny (Аvitsenny) [Medical system of Ibn Sina (Avicenna)]. Dushanbе, RT: Donish; 2005. 300 p.
  11. Dedov II, Shestakova MV. Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol’nim sakharnym diabetom [Algorithms for specialized medical care for patients with diabetes]. Sakharnyy diabet. 2017;20(IS):1-112.
  12. American Diabetes Association: Preconception care of women with diabetes (Position Statement). Diabetes Care. 2002;25(Suppl.):82-4.
  13. Mikhaylichenko VYu, Stolyarov SS. Rol’ insulyarnykh i kontrinsulyarnykh gormonov v patogeneze alloksanovogo sakharnogo diabeta u krys v eksperimente [The role of insular and contra- insular hormones in the pathogenesis of alloxan diabetes in rats in an experiment]. Sovremennye problemy nauki i obrazovaniya. 2015;4:485.
  14. Unwin N, Shaw J, Zimmet P, Alberti G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetes Med. 2002;19:1-17.
  15. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015;3(2):105- 13.
  16. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. Obnovlyonnye klinicheskie rekomendatsii po diagnostike i lecheniyu sakharnogo diabeta Amerikanskoy assotsiatsii klinicheskikh endokrinologov (AACE) i Amerikanskogo koledzha endokrinologov (ACE) [Updated clinical guidelines for the diagnosis and treatment of diabetes by the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinologists (ACE)]. Diabet. Ozhirinnya. Metabolichniy sindrom. 2015;4(4):17-21.
  17. Mamedov МN, Poddubskaya ЕА, Kovrigina МN, Ugurchieva ZО, Digigova RТ. Pervichnaya profilaktika sakharnogo diabeta: korrektsiya rannikh narusheniy uglevodnogo obmena v kardiologicheskoy praktike [Primary prevention of diabetes: correction of early disorders of carbohyrate metabolism in cardiology practice]. Ratsional’naya farmakoterapiya v kardiologii. 2012;8(1):81-7.
  18. Marchetti P, Bugliani M, Boggi U, Masini M, Marselli L. The pancreatic β cells in human type 2 diabetes. Adv Exp Med Biol. 2012;771:288-309.
  19. Meier JJ, Bonadonna RC. Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes. Diabetes Care. 2013;36 (Supplement 2): S113-S119.
  20. Saisho Y. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World Journal of Diabetes. 2015;6(1):109.
  21. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
  22. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiological Reviews. 2011;91(2):733-94.
  23. Ghezzi Ch, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087-97.
  24. Abdul-Ghani M, DeFronzo R. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Practice. 2008;14(6):782-90.
  25. Scheen AJ. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Research and Clinical Practice. 2016;121:204-14.
  26. Kimura G. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. Journal of the American Society of Hypertension. 2016;10(3):271-8.
  27. Kiselyova ТL, Smirnona YuА, Blinkov IL, Dronova МА, Tsvetaeva ЕV. Kratkaya entsiklopediya sovremennoy fitoterapii s osnovami gomeopatii: spravochnik prakticheskogo vracha [A brief encyclopedia of modern herbal medicine with the basics of homeopathy: a practitioner’s guide]. Moscow, RF: Isd-vo Professional’noy assotsiatsii naturoterapevtov; 2010. 592 p.
  28. Kurkina АV. Flavonoidy farmakopeynykh rasteniy [Flavonoids of pharmacopoeial medicinal plants]. Samara, RF: ООО «Ofort»; 2012. 290 p.
  29. Pilat ТL, Kuzmina LP, Izmerova NI. Detoksikatsionnoe pitanie [Detox nutrition]. Moscow, RF: GEOTAR-Media; 2012. 688 p.
  30. Shepelev АP, Shovkun LА. Perikisnoe okisleniе lipidov i sistemа antioksidantov v normе i pri patologii [Lipid peroxidation and the antioxidant system in normal and pathological conditions]. Rostov-nа-Donu, RF: RostGMU; 2012. 363 p.
  31. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-99.
  32. Mikaelyan NP, Nguen KhZ, Mikaelyan АА. Narushenie obmena zhirnych kislot pri ozhirenii i sakharnom diabete 2 tipa u zhenshchin s insulinoreziztentnost’yu [Impaired fatty acid metabolism in obesity and type 2 diabetes in women with insulin resistance]. Rossiyskiy meditsinskiy zhurnal. 2015;21(6):28-32.
  33. Ng JM, Azuma K, Kelley C, Pencek R, Radikova Z, Laymon C, et al. PET imaging reveals distinctive roles for different regional adipose tissue depots in systemic glucose metabolism in nonobese humans. American Journal of Physiology-Endocrinology and Metabolism. 2012;303(9):E1134-E1141.
  34. Perry RJ, Camporez J-PG, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745-58.
  35. Ferris HA, Kahn CR. Unraveling the paradox of selective insulin resistance in the liver: the brain-liver connection. Diabetes. 2016;65(6):1481-3.
  36. Costabile G, Annuzzi G, Di Marino L, De Natale C, Giacco R, Bozzetto L, et al. Fasting and post-prandial adipose tissue lipoprotein lipase and hormone-sensitive lipase in obesity and Type 2 diabetes. Journal of Endocrinological Investigation. 2011;34(5):e110-e114.
  37. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta. 2014;1841(7):919-33.
  38. Hegele RA. Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes. Journal of Lipid Research. 2016;57(9):1601-7.
  39. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Current Diabetes Reports. 2010;10(4):306-15.
  40. Kolka CM, Richey JM, Castro AVB, Broussard JL, Ionut V, Bergman RN. Lipid-induced insulin resistance does not impair insulin access to skeletal muscle. American Journal of Physiology-Endocrinology and Metabolism. 2015;308(11):E1001-E1009.
  41. DeFronzo R. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-87.
  42. Gonçalves CG, Glade MJ, Meguid MM. Metabolically healthy obese individuals: Key protective factors. Nutrition. 2016;32(1):14-20.
  43. DeClercq V, d’Eon B, McLeod RS. Fatty acids increase adiponectin secretion through both classical and exosome pathways. Biochim Biophys Acta. 2015;1851(9):1123-33.
  44. Verbovoy АF, Morkovskich NV. Markyory endokrinnoy sistemy i vospaleniya kak prognosticheskie faktory riska razvitiya sosudistykh oslozhneniy pri sakharnom diabete 2 tipa [Markers of the endocrine system and inflammation as prognostic risk factors for the development of vascular complications in type 2 diabetes]. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2011;3:37-42.
  45. Dedov II, Shestakova MV. Sakharniy diabet [Diabetes mellitus]. Moscow, RF: Universum Pablishing; 2003. 455 p.
  46. Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diabetes and Vascular Disease Research. 2013;10(6):472-82.
  47. Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, et al. Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels. Diabetes. 2017;66(9):2472-82.
  48. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders. 2010;11(1):61-74.
  49. Suganya N, Bhakkiyalakshmi E, Sarada D, Ramkumar K. Reversibility of endothelial dysfunction in diabetes: role of polyphenols. British Journal of Nutrition. 2016;116(02):223-46.
  50. Ryabchenko АYu, Dolgov АM, Denisov ЕN, Aptikeeva NV, Tumanova NG. Markyory disfunktsii endoteliya pri ishemicheskom insul’te v zavisimosti ot ego patogeneticheskikh podtipov [Markers of endothelial dysfunction in ischemic stroke depending on its pathogenetic subtypes]. Doktor. RU. 2016;4:22-5.
  51. Soboleva GN, Fedulov VK, Samko AN, Levitskiy IV, Rogoza АN, Balakhonova ТV, Karpov YuА. Prognosticheskoe znachenie disfunktsii endoteliya koronarnykh i plechevoy arterii, traditsionnykh faktorov riska v razvitii serdechno-sosudistykh oslozhneniy u patsientov s mikrososudistoy stenokardiey [Prognostic value of coronary and brachial artery endothelial dysfunction, traditional risk factors in the development of cardiovascular complications in patients with microvascular angina]. Rossiyskiy kardiologicheskiy zhurnal. 2017;3:54-8.
  52. Inzhutova АI, Salmina АB, Petrova MM. Rol’ CD38 v mezhkletochnykh vzaimodeystviyakh pri endotelial’noy disfunktsii [The role of CD38 in intercellular interactions in endothelial dysfunction]. Byulleten’ eksperimental’noy biologii i meditsiny. 2008;145(6):648-51.
  53. Pirro M, Schillaci G, Bagaglia F. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis. 2008;197(2):57-67.
  54. Zubairov DМ, Zubairova LD. Mikrovezikuly v krovi, funktsiya i ikh rol’ v tromboobrozovanii [Microvesicles in the blood, function and their role in thrombosis]. Moscow, RF: GEOTAR-Media; 2009. 168 p
  55. Kuznik BI. Kletochnye i molekulyarnye mekhanizmy regulyatsii sistemy gemostaza v norme i patologii [Cellular and molecular mechanisms of regulation of the hemostatic system in normal and pathological conditions]. Chita, RF: Ekspress-izdatel’stvo; 2010. 832 p.
  56. Alfonsova ЕV, Kuznik BI. Vliyanie metabolicheskogo atsidoza na strukturnuyu organizatsiyu endoteliya [The effect of metabolic acidosis on the structural organization of the endothelium]. Fundamental’nye issledovaniya. 2014;10- 8:1451-5.
  57. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. Journal of Diabetes. 2017;9:434-49.
  58. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circulation Research. 2016;118:1808-29.
  59. Panigrahy SK, Bhatt R, Kumar A. Reactive oxygen species: sources, consequences and targeted therapy in type 2 diabetes. Journal of Drug Targeting. 2017;25(2):93-101.
  60. Galstyan GR, Galyavich AS, Grinyova EN, Gurevich VS, Ezhov MV, Kalashnikov VYu, i dr. Vozmozhnosti lipidsnizhayushchey terapii v uluchshenii prognoza u patsientov s ateroskleroticheskimi serdechno-sosudictymi zabolevaniyami i sakharnym diabetom: rol’ ingibitorov PCSK 9 [The potential of lipid-lowering therapy in improving prognosis in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of inhibitors of PCSK9]. Rossiyskiy kardiologicheskiy zhurnal. 2018;23(12):103-6.
  61. Goligorsky MS. Vascular endothelium in diabetes. American Journal of Physiology-Renal Physiology. 2017;312(2):F266-F275.
  62. Ciccone MM, Scicchitano P, Cameli M, Cecere A, Cortese F, Dentamaro I, et al. Endothelial function in pre-diabetes, diabetes and diabetic cardiomyopathy: a review. J Diabetes Metab. 2014;5(4):1000364.
  63. Shestakova МV. Kommentarii endokrinologa k rekomendatsiyam po sakharnomu diabetu, prediabetu i serdechno-sosudistym zabolevaniyam ESC-EASD 2007 [Endocrinologist’s comments on diabetes, prediabetes and cardiovascular disease recommendations ESC-EASD 2007]. Sakharnyy diabet. 2008;11(1):97-9.
  64. Botnariu G, Bulgaru-Iliescu D. Determinant factors of cardiovascular mortality in type 2 diabetic patients: literature review. Rom J Leg Med. 2010;18(4):309-14.
  65. Roshchin DО, Sabgayda ТP, Evdokushina GN. Problema uchyota nalichiya sakharnogo diabeta pri diagnostike prichin smerti [The problem of accounting for the presence of diabetes in the diagnosis of causes of death]. Sotsialnye aspekty zdorov’ya naseleniya. 2012;5:1-13.
  66. Henry RR. DURATION‑1 extension: efficacy and tolerability of exenatide once weekly (QW) over 6 years in patients with T2DM. Diabetes. 2014;63:A247.
  67. Home PD. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17:179-87.
  68. Storgaard H, Bagger JI, Knop FK, Vilsbøll T, Rungby J. Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment. Basic Clin Pharmacol Toxicol. 2016;118:168-70.
  69. Erickson SC, Le L, Zakharyan A, Stockl KM, Harada AS, Borson S, et al. New‐ onset treatment‐dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. Journal of the American Geriatrics Society. 2012;60(3):474-9.
  70. Gonzalez-Bulnes A, Astiz S, Ovilo C, Garcia-Contreras C, Vazquez-Gomez M. Nature and nurture in the early-life origins of metabolic syndrome. Current Pharmaceutical Biotechnology. 2016;17(7):573-86.
  71. Nuraliev YuN, Sharofova MU, Sagdieva ShS. O sushchnosti i tyazhyolykh posledstviyakh taktiki terapii sakharnogo diabeta po printsipu «podobnoe podobnym» [Essence and severe consequences of therapy tactics of diabetes mellitis by principle «like cures like»]. Vestnik Avitsenny [Avicenna Bulletin]. 2015;3:151-6.
  72. Sharofova M, Aldybiat I, Sagdieva Sh, Burkhonova N, Nuraliev Yu, Rahimi F, Mirshahi M. Molecular approach to determine the hot and cold temperaments in plants according Avicenna concepts, the role of magnesium. Vestnik Avitsenny [Avicenna Bulletin]. 2018;20(4):421-6. Available from: http:// dx.doi.org/10.25005/2074-0581-2018-20-4-421-426.
  73. Kulikova NG, Baytokova RR. Mediko-sotsial’nye problemy sakharnogo diabeta. Problemy sotsial’noy gigieny, zdravookhraneniya i istorii meditsiny. 2011;2:23-4.
  74. Khabriev RU, Malichenko VS, Malichenko SB. Problemy lekarstvennogo obespecheniya bol’nykh diabetom 2-go tipa [The problems of pharmaceutical support of patients with diabetes mellitus type II]. Problemy sotsial’noy gigieny, zdravookhraneniya i istorii meditsiny. 2016;24(4):196-200.

Authors' information:

Sharofova Mizhgona Umedzhonovna
Candidate of Medical Sciences, Head of the Biotechnology Laboratory, Department of Innovative Pharmacology and Experimental Medicine of the Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan; Director of Institute of Avicenna’s Medicine and Pharmacology
ORCID ID: 0000-0002-7155-7194

Sagdieva Shoista Samarovna
Candidate of Medical Sciences, Senior Researcher, Department of Innovative Pharmacology and Experimental Medicine of the Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan; Scientific Secretary of the Institute of Avicenna’s Medicine and Pharmacology
ORCID ID 0000-0002-0595-3666

Yusufi Salomudin Dzhabbor
Academician of the Academy of Medical Sciences of the Republic of Tajikistan, Doctor of Pharmaceutical Sciences, Full Professor, Vice Rector for Science and Publishing, Avicenna Tajik State Medical University
ORCID ID 0000-0002-1442-9508

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment.

Conflicts of interest: No conflict

Address for correspondence:

Sharofova Mizhgona Umedzhonovna
Candidate of Medical Sciences, Head of the Biotechnology Laboratory, Department of Innovative Pharmacology and Experimental Medicine of the Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan; Director of Institute of Avicenna’s Medicine and Pharmacology

734025, Republic of Tajikistan, Dushanbe, 229/3 Ayni Street

Tel.: +992 (918) 614123

E-mail: mijgona72@mail.ru

◄ Back to the list